WHAT'S KNOWN ON THIS SUBJECT: In HIV-infected children, decisions to start antiretroviral therapy must weigh immunologic benefits against potential risks. Current guidelines recommend using CD4 percentage and age when deciding to start treatment. Population-level effects of these factors on immunologic recovery are unknown.
Determining optimal timing for initiation of highly active antiretroviral therapy (HAART) in children infected with HIV remains a challenge. Globally in 2012, 3.3 million children were living with HIV, and 210 000 children died due to AIDS. 1 Although HAART has improved long-term survival, 2 only 34% of eligible children currently receive treatment. 1 Treatment guidelines must consider public health implications for not only disease progression, 2,3 but also long-term complications of drug toxicities, 4 inadequate adherence, [5] [6] [7] resistance mutations, 5 and cost-effectiveness. For HIV-infected infants, immediate HAART initiation is clearly needed, given its strong survival benefit, 8, 9 improved neurodevelopmental outcomes, 10 faster growth recovery, 11 and the population' s high mortality. 12, 13 However, for HIV-infected children presenting outside of infancy with minimal HIVrelated symptoms, the clinical benefits of early HAART initiation are unclear. 14, 15 Quantifying immunologic benefits of treatment initiation at different CD4 percentage (CD4%) and age thresholds may inform public health decisions regarding optimal HAART initiation timing.
Population-level immunologic effects of HAART initiation at different CD4% and age combinations have been poorly quantified because most previous studies have only assessed associations. HIV-infected children who initiate HAART at lower CD4% reach lower peak CD4 levels, 4, [16] [17] [18] [19] [20] [21] [22] [23] [24] perhaps from persistent effects of chronic immune activation. 25, 26 HAART initiation at younger ages is associated with better immunologic recovery. [17] [18] [19] [20] 24, 27, 28 Some longitudinal studies have quantified long-term CD4 trajectories on HAART based on pretreatment CD4 and age, allowing predictions that are child-specific. 24, 29 However, projected immunologic impacts at population levels have not been established.
Our aim was to quantify populationlevel impacts of HAART initiation at different CD4% and age thresholds on CD4% recovery. Our primary outcome was the proportion of immunosuppressed children ever achieving a normal CD4% ($10th percentile for age 30 ) within 4 years of HAART initiation. Secondary outcomes were CD4% at 4 years after HAART initiation and the proportion of children with a normal CD4% at 4 years. The proportion of immunosuppressed children ever having a normal CD4% within 4 years of HAART initiation reflects biological capacity for CD4% reconstitution. The CD4% and proportion of children normal at 4 years reflect outcomes inclusive of initial CD4% recovery, potential immunologic failure, and possible immune restoration on a subsequent regimen.
METHODS

Participants
PENPACT-1 (Pediatric AIDS Clinical Trials Group 390/Paediatric European Network for Treatment of AIDS 9) 31 was an international, multicenter, phase 2/3, randomized, open-label, 2-by-2 factorial trial enrolling HIV-1-infected children (aged .30 days to ,18 years) in Europe, North America, and South America between September 25, 2002, and September 7, 2005 . Eligible children had not been treated with antiretrovirals or only received antiretrovirals to reduce motherto-child transmission (excluding singledose nevirapine) for ,56 days and met local indications for HAART.
Procedures
At entry, children were randomly assigned (1:1) in 2-by-2 factorial design:
(1) to start HAART with 2 nucleoside reverse transcriptase inhibitors plus either a protease inhibitor or nonnucleoside reverse transcriptase inhibitor and (2) to switch from first-line to second-line HAART at viral load thresholds of either 1000 copies/mL or 30 000 copies/mL. CD4% and HIV RNA viral loads were measured at randomization (baseline, week 0); weeks 2, 4, 8, 12, 16, 24; and then every 12 weeks until the last enrollee reached 4 years of follow-up (August 31, 2009) . Full study details are described elsewhere. 31 Because previous PENPACT-1 analyses found no significant differences among randomized arms, 31 we pooled participants across arms. To minimize confounding from unknown duration of infection, analyses were restricted to participants who were infected vertically.
For the primary outcome (CD4% recovery within 4 years), data from vertically infected children with at least "mild" immunosuppression at baseline by World Health Organization (WHO) Immunologic Classification 32 and CD4% ,10th percentile for age 30 were analyzed to determine the proportion of children who improved to normal CD4% ($10th percentile for age 30 ) at any time within 4 years of follow-up. For secondary outcomes, data from all vertically infected children, regardless of baseline immune status, were analyzed for outcomes at 4 years after HAART initiation: CD4% and proportion of children with normal CD4% (see definitions in the next section).
Definitions
To account for age-related variability of CD4%, we defined normal CD4% recovery based on data from healthy, urban-dwelling, pediatric patients in the United States. 30 For the primary outcome, recovery to normal was defined as 2 consecutive CD4% measurements $10th percentile-for-age. Time of recovery was defined as the first of these CD4% measurements. Participants lost to follow-up without recovery were censored in Kaplan-Meier analyses and counted as failures in regression analyses.
For secondary outcomes, CD4% at 4 years was defined as the mean of CD4% measurements at weeks 192 and 204. At week 192, all participants were $3 ARTICLE years old, and CD4% 10th percentilefor-age after 3 years old ranges between 28% to 31% without a consistent age-related trend. Thus, the definition of normal CD4% at 4 years was simplified to be mean CD4% $30%. 30, 33 Participants missing 4-year CD4% measurements were excluded from secondary outcome analyses.
Baseline CD4% was categorized according to a modified version of the WHO Immunologic Classification for HIV-Associated Immunodeficiency. 32 As this classification switches to CD4 cell counts after age 5 years, we used the following immunodeficiency (CD4%) categories for subjects $5 years (same as ages 3 to ,5 years; see also the Centers for Disease Control and Prevention [CDC] HIV infection classification systems 34, 35 ) : "none/not significant" .25%, "mild" 20% to 25%, "advanced" 15 to ,20%, and "severe" ,15%.
Statistical Analysis
Bivariate categorical analyses were performed by using Fisher' s exact test. Continuous variables were analyzed by using linear regression. Trend linearity was assessed by using polynomial expansion and restricted quadratic splines with knots between quintiles.
Recovery to normal CD4% within 4 years was analyzed by Kaplan-Meier methods with log-rank statistics and modified Poisson regression on an additive scale with Huber-White variance estimators (additive Poisson). 36, 37 CD4% at 4 years was analyzed by using multivariable linear regression while having normal CD4% at 4 years used additive Poisson regression. Models were constructed by using published literature and hypothesis-driven a priori assumptions to guide statistical assumptions, 38, 39 then reduced by backward elimination using P , .15 and .10% change-inestimate criteria. Models estimating baseline CD4% main effects were adjusted for age, gender, and race. Models estimating age main effects were adjusted for gender and race. Interactions between immunologic classification and age were assessed and retained in models if P , .15. Hypothesis tests in Poisson regression used score statistics; linear regression used likelihood ratio tests. Statistical significance was defined as 2-sided P , .05.
Models were not adjusted for adherence or viral failure because both variables are on the causal pathway to CD4% recovery. 38 Adjustment for adherence or viral failure would control for information unavailable to clinicians when making decisions about treatment initiation and would add bias to estimates. 40 However, we evaluated viral failure to assess the degree to which immunologic outcomes may be explained by poor viral control. Viral failure was defined as (1) failure to suppress HIV RNA viral load to #400 copies/mL by week 24 of HAART or (2) after initial viral suppression, viral load .400 copies/mL for 2 consecutive measurements, the first occurring by week 192. Analyses used Cox models for testing associations and stratified proportional hazards models 41 to estimate adjusted Kaplan-Meier failure probabilities. CD4% main effect estimates were adjusted for age, continent, and baseline viral load. Age main effect estimates were adjusted for continent.
Alosstofollow-up(LTFU)analysisevaluated bivariate relationships between baseline characteristics and missing CD4% values at 4 years. To assess the potential influence of LTFU on results, sensitivity analyses corrected CD4% outcomes at 4 years for LTFU by using a method similar to direct standardization (inverse-probability weighting methods). 42 Statistical analyses used SAS version 9.3 (Cary, NC). This study is registered with International Standard Randomised Controlled Trial Number Register (ISRCTN73318385). The study protocol was deemed exempt by institutional review boards at Duke University and University of North Carolina.
RESULTS
Baseline Characteristics and Overall Estimates
PENPACT-1 enrolled 266 children infected with HIV-1 from 68 centers in 13 countries in Europe, North America, and South America; 263 were included in the main trial analysis. For analysis of CD4% recovery within 4 years, 162 participants with baseline immunosuppression were included, and 209 qualified for analyses of CD4% status at 4 years (Supplemental Fig 4) . The baseline characteristics of all 209 vertically infected participants are shown in Table 1 . At baseline, WHO-staged CD4% was associated with age, race, and gender; marginally associated with continent and CDC clinical stage; and not associated with growth parameters (weight-forage z score, height-for-age z score, and BMI-for-age z score) or baseline viral load. Age at HAART initiation was associated with race, continent, growth parameters, baseline viral load, and baseline CD4% but not associated with gender or CDC clinical stage.
Eighty-seven percent (182 of 209) of participants had follow-up CD4% measurements at 4 years. LTFU was only associated with continent (Europe 5%, North America 27%, South America 10%; P , .001). Correcting for LTFU did not meaningfully alter study results (data not shown).
Of 162 children with baseline immunosuppression, the estimated probability of achieving a normal CD4% within 4 years was 72% (95% confidence interval [CI]: 64% to 78%); mean CD4% at 4 years was 30.9 (95% CI: 29.5 to 32.3); 56% of participants (95% CI: 48% to 64%) had normal CD4% at 4 years. Of 209 children with any baseline immune status, mean CD4% at 4 years was 32.8 (95% CI: 31.5 to 34.2), with 64% (95% CI: 57% to 71%) of children having normal CD4% at 4 years.
Baseline CD4%
CD4% recovery within 4 years was significantly associated with WHO-staged baseline CD4% (Kaplan-Meier, P , .001; Fig 1) . In regression models, baseline CD4% was significantly associated with all three 4-year CD4% outcomes: proportion of immune suppressed children ever recovering a normal CD4% within 4 years (unadjusted P , .001, adjusted P , .001; Fig 1) ; CD4% at 4 years (unadjusted P , .001, adjusted P , .001; Table 2 ); and proportion of children normal at 4 years (unadjusted P , .001, adjusted P , .001; Table 2 ). Compared with WHO "severe" immunosuppression, each increase in baseline CD4% category had an increasing trend in proportion of children ever nor-mal within 4 years (Fig 1) , CD4% at 4 years (Table 2) , and proportion of children normal at 4 years ( Table 2) .
Age at HAART Initiation
CD4% recovery within 4 years was significantly associated with age (Kaplan-Meier, P , .001; Fig 2) . The association between age and CD4% recovery was approximately linear (by significance testing) for all three 4-year CD4% outcomes ( Fig 3A-3C) . In multivariable linear regressions adjusting for gender and race, each 5-year increase in age at HAART initiation had an estimated (1) reduction of 19% in proportion of children ever having a normal CD4% within 4 years (95% CI: 11% to 27%; P , .001),
(2) decrease in CD4% at 4 years of 2.9 percentage points (95% CI: 1.4% to 4.3%; P , .001), and (3) reduction in proportion of children with a normal CD4% at 4 years of 7% (95% CI: -1% to 16%; P = .08).
Combined Effects of Baseline CD4% and Age
The interaction between baseline CD4% and age on the probability of ever recovering a normal CD4% within 4 years was statistically significant (unadjusted P = .009, adjusted P = .02; Table 3 ). This interaction was synergistic: with increasing age, baseline CD4% had a stronger effect on the capacity to recover a normal CD4% within 4 years. However, interactions (41) 13 (13) 18 (18) 27 (27) 99 .07 2.0 (1.5) N/A 5-9 y 27 (39) 18 (26) 12 (17) 13 ( (34) 18 (17) 25 (24) 25 (24) 103 .003 5.6 (4.5) .59 Male 56 (53) 22 (21) 9 (8) 19 (18) 106 6.0 (4.6) Race, n (%)
Black, non-Hispanic 48 (42) 26 (23) 22 (19) 18 (16) 114 .04 6.8 (4.8) ,.001 White, non-Hispanic 12 (34) 5 (14) 3 (9) 15 (43) (43) 26 (28) 13 (14) 15 (16) 94 .05 5.0 (3.9) .002 North America 30 (48) 10 (16) 9 (14) 14 (22) 63 7.4 (5.5) South America 21 (40) 4 (8) 12 (23) 15 (29) (37) 24 (22) 24 (22) 22 (20) 111 .06 5.9 (4.8) .78 B or C 50 (51) 16 (16) 10 (10) 22 (22) 98 5.7 (4.1) Treatment regimen, n (%) NNRTI 46 (43) 16 (15) 22 (21) 22 (21) 106
45 (44) 24 (23) 12 (12) 22 (21) 103 6.3 (4.9) Switching threshold, n (%) 1000 copies/mL 46 (44) 19 (18) 14 (13) 25 (24) 104 N/A b 5.6 (4.5) N/A b 30 000 copies/mL 45 (43) 21 (20) 20 (19) 19 (18) between baseline CD4% and age were not significant for CD4% at 4 years (unadjusted P = .91; adjusted P = .91) or the proportion of children with normal CD4% at 4 years (unadjusted P = .50, adjusted P = .59; Table 4 ).
A model including baseline CD4%, age, gender, race, and a baseline CD4%-byage interaction predicted .90% probability of CD4% recovery within 4 years when initiating HAART with "mild" immunosuppression at any age or with "advanced" immunosuppression at age ,3 years. Adolescents with WHO "severe" immunosuppression had the lowest recovery probabilities, but the small sample size of adolescents made these estimates imprecise (Table 3) . Trends were similar for CD4% outcomes at 4 years (Table 4 ).
Viral Failure
Of 209 vertically infected participants, 82 (39%) experienced viral failure within 4 years. Twenty-nine (14%) failed to suppress to #400 copies/mL by week 24, and 53 (25%) suppressed but experienced viral rebound to .400 copies/mL. One participant (0.5%) was LTFU before week 24. Viral failure was not associated (Cox model, unadjusted P = .36, adjusted P = .23) with baseline immunodeficiency classification (adjusted Kaplan-Meier failure probability: "none" 32%, "mild" 54%, "advanced" 44%, "severe" 40%). Viral failure and age had a bimodal relationship (Cox model, unadjusted P , .001, adjusted P , .001) with peaks in infancy and adolescence (adjusted Kaplan-Meier failure probability: 0 to ,1 year 56%, 1 to ,3 years 34%, 3 to ,5 years 32%, 5 to ,8 years 24%, 8 to ,13 years 38%, 13 to , 18 years 63%; Fig 3D) .
DISCUSSION
On the basis of these PENPACT-1 results, initiating HAARTat healthier immunologic stages and younger ages may have profound impacts on immunologic recovery. We suggest that HAART initiation when children first have "mild" immunosuppression would result in almost all children experiencing full CD4% recovery. Similarly, HAART at younger ages would yield high probabilities of immune recovery and may blunt negative effects of "severe" immunosuppression. Although not all children maintained immune recovery (demonstrated by more attenuated immunologic benefits at 4 years) most CD4% outcomes at 4 years were still improved in children starting HAART at healthier CD4 levels and younger ages. Our results quantify the magnitude of these effects on immunologic outcomes to help inform public health planning.
The PENPACT-1 data align with US Department of Health and Human Services (DHHS) pediatric HIV treatment guidelines. 3, 43 The DHHS recommends initiating HAART in all HIV-infected infants and any HIV-infected children with AIDS or most CDC Clinical Category B or C conditions; confirmed plasma HIV RNA levels
FIGURE 1
Cumulative proportion of children with CD4% recovery to normal versus weeks after HAART initiation, by baseline WHO Immunodeficiency Classification ("mild," "advanced," "severe"). Primary outcome is CD4% $10th percentile for age by week 192, marked by vertical dashed line. P value is from log-rank statistic.
.100 000 copies/mL; aged 1 to ,3 years with CD4 cell count ,1000 cells/mm 3 or CD4% ,25%; ages 3 to ,5 years with CD4 count ,750 cells/mm 3 or ,25%; or age $5 years with CD4 count ,500 cells/mm 3 (with considerations for treating at higher CD4 levels). 43 DHHS-recommended CD4% and age treatment thresholds correspond to WHO immunodeficiency classifications of "advanced" for ages 1 to ,3 years and "mild" for all age categories $3 years. If all children aged 1 to ,13 years in PENPACT-1 had initiated HAART immediately after reaching DHHS-recommended CD4% and age treatment thresholds, we estimate .90% of these children would have experienced CD4% recovery to normal within 4 years, and .80% would have had a normal CD4% at 4 years.
Evidence supporting early treatment is strongest in infants. A randomized controlled trial (RCT) of HIV-infected infants in South Africa found that, compared with delaying treatment until infants met prespecified clinical or CD4% criteria, immediate HAART initiation reduced early infant mortality by 76% and HIV progression by 75%. 8 Infants with immediate treatment had better gross motor and general neurodevelopmental scores, 10 and treatment ,6 months old may have faster improvements in weight-forage and head circumference-for-age z scores. 11 A Cochrane review on effectiveness of HAART in HIV-infected children ,3 years old concluded that immediate HAART reduces morbidity and mortality in infants, but clinical benefits of universal treatment initiation in children aged 1 to 3 years remain unclear. 9 Evidence for early treatment in children $1 year old is less compelling. An RCT in Thailand and Cambodia of HIVinfected children aged 1 to 12 years with CD4% 15% to 24% found that immediate versus delayed HAART resulted in similar 144-week AIDS-free survival (98.7% vs 97.9%) but improved height z scores and higher CD4% (33.2% vs 24.8%). 15 Neurodevelopmental scores were no different across arms. 14 Links among pretreatment CD4, age, and long-term CD4 recovery have been established in literature. [17] [18] [19] [20] 24 However, our estimates allow the reader to quantify population-level immunologic benefits of early versus delayed treatment at combinations of CD4% and age.
Adolescent recommendations are based primarily on adult data. 44 Adult RCTs found decreased AIDS progression or death with HAART in patients with acute opportunistic illnesses, 45 CD4 ,200 cells/ mm 3, 46 or CD4 200 to ,350 cells/mm 3 . 47 Adult cohort studies suggest that initiating HAART at CD4 counts 350 to 500 cells/mm 3 reduces HIV-related disease progression but have conflicting results at CD4 .500 cells/mm 3 . [48] [49] [50] [51] Adult data further support earlier treatment to enhance CD4 recovery 52 and prevent HIV sexual transmission. 53 Consequently, DHHS guidelines recommend universal HAART in all HIV-infected adults and adolescents. 44 From our PENPACT-1 results, we are concerned by the poor outcomes in older children and adolescents, particularly those with poor baseline immunologic status. Biologically, we expected relationships between CD4% recovery and age to plateau because thymic potential stabilizes as children approach adult immune maturity. 24, 27, 28 Instead, CD4% outcomes declined through adolescence, likely from increasing adherence struggles and viral failure. 7, 54 Consistent with child-specific predictions, 24 older children and adolescents may benefit most dramatically from earlier HAART initiation (complementary to strategies for better case finding, adherence, or therapeutic approaches for improving immunologic potential).
Immunologic benefits of earlier treatment should be weighed against potential harms. In PENPACT-1, viral failure was worse at age extremes, consistent with studies finding poor viral suppression at younger ages 6, 19 and myriad adherence difficulties in adolescents. 7, 54 For some children, immunologic recovery is transient, and starting HAART earlier may eventually lead to fewer treatment options. Fortunately, HAART initiation at higher CD4 counts may mitigate antiretroviral resistance at viral failure. 55 Still, diminishing immunologic benefits over time and viral failure risks highlight the importance of long-term longitudinal studies for understanding implications of different HAART strategies in children.
Our study was limited by including only participants from a clinical trial in predominantly industrialized countries.
Results may not generalize to other settings. Low sample sizes in certain CD4% and age strata, particularly adolescents, decreased precision of estimates and precluded more intricate model specification. Finally, analysis of potential sources of bias 38 suggested possible unmeasured confounding from host immunology and HIV virulence, which were untestable in our data. 
CONCLUSIONS
FIGURE 2
Cumulative proportion of children with CD4% recovery to normal versus weeks after HAART initiation, by age at HAART initiation (0-4, 5-9, 10-17 years). Primary outcome is CD4% $10th percentile for age by week 192, marked by vertical dashed line. P value is from log-rank statistic. Mild, n = 31 97 (88% to 100%) 96 (88% to 100%) 96 (87% to 100%) 95 (86% to 100%) 93 (82% to 100%) 91 d (76% to 100%) 95 (86% to 100%) Advanced, n = 40 95 (75% to 100%) 92 (74% to 100%) 86 (72% to 100%) 80 (68% to 92%) 70 (53% to 86%) 56 (27% to 85%) 80 (68% to 92%) Severe, n = 91 83 (69% to 98%) 77 (65% to 90%) 69 (59% to 78%) 59 (50% to 68%) 44 (31% to 56%) 22 (0% to 44%) 59 (50% to 68%) Overall, e n = 162 94 (83% to 100%) 88 (79% to 97%) 80 (73% to 86%) 70 (64% to 77%) 56 (46% to 65%) 35 (18% to 52%) 71 (65% to 77%) a Additive Poisson regression estimates; adjusted for age, gender, race, and interaction between WHO Immunologic Classification and age; estimated at the covariate distribution of primary outcome subset. b Wald upper 95% confidence limits exceeding 100% were rounded to 100%. c Overall WHO category estimates are at the primary endpoint subset mean age (6.3 y). d n = 0 for this cell. e Overall age estimates are adjusted for gender and race only. None, n = 37 99 (88% to 100%) 97 (87% to 100%) 93 (85% to 100%) 89 (80% to 98%) 83 (70% to 96%) 74 (53% to 96%) 90 (81% to 99%) Mild, n = 27 86 (67% to 100%) 83 (65% to 100%) 80 (63% to 97%) 76 (59% to 93%) 70 (51% to 89%) 61 d (36% to 86%) 77 (60% to 94%) Advanced, n = 38 74 (55% to 94%) 72 (54% to 90%) 69 (52% to 85%) 65 (49% to 80%) 59 (42% to 75%) 50 (28% to 71%) 66 (50% to 81%) Severe, n = 80 56 (41% to 70%) 53 (41% to 66%) 50 (39% to 61%) 46 (35% to 57%) 40 (27% to 53%) 31 (11% to 52%) 47 (36% to 58%) Overall, e n = 182 75 (64% to 85%) 72 (63% to 81%) 68 (60% to 75%) 63 (56% to 70%) 56 (45% to 66%) 45 (27% to 63%) 64 (58% to 71%) a Additive Poisson regression estimates; adjusted for age, gender, and race; estimated at covariate distribution of secondary outcomes subset. b Wald upper 95% confidence limits exceeding 100% were rounded to 100%. c Overall WHO category estimates are at the secondary end point subset mean age (5.8 y) . d n = 0 for this cell. e Overall age estimates are adjusted for gender and race only.
